Cargando…
Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) is still a consolidation treatment choice for relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients and some aggressive B-cell NHL as frontline therapy. Due to the shortage of carmustine, we switc...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895978/ https://www.ncbi.nlm.nih.gov/pubmed/33608570 http://dx.doi.org/10.1038/s41598-021-81944-8 |
_version_ | 1783653467370291200 |
---|---|
author | Tian, Chen Li, Yueyang Liu, Su Chen, Zehui Zhang, Yizhuo Yu, Yong Yang, Hongliang Zhao, Haifeng Zhao, Zhigang Yuan, Tian Wang, Yafei |
author_facet | Tian, Chen Li, Yueyang Liu, Su Chen, Zehui Zhang, Yizhuo Yu, Yong Yang, Hongliang Zhao, Haifeng Zhao, Zhigang Yuan, Tian Wang, Yafei |
author_sort | Tian, Chen |
collection | PubMed |
description | High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) is still a consolidation treatment choice for relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients and some aggressive B-cell NHL as frontline therapy. Due to the shortage of carmustine, we switched to idarubicin-substituted BEAC (IEAC) conditioning regimen. We retrospectively compared the outcomes of 72 aggressive B-cell NHL patients treated with IEAC or BEAC regimens followed by ASCT as upfront consolidative treatment. The median time to neutrophil and platelet reconstitution showed no difference between IEAC and BEAC groups. IEAC regimen was well tolerated without increase of adverse events. Transplant-related mortality didn’t occur. The overall survival (OS) and progression-free survival (PFS) of IEAC group (33 and 23 months) were a little longer than that of BEAC group (30 and 18 months). However, due to the small sample numbers, there’s no significant difference in OS and PFS between IEAC and BEAC group with DLBCL or MCL. Multivariate analysis showed that AnnArbor staging, IPI score, lactate dehydrogenase level, remission of disease, modified regimen were related with PFS and OS. In conclusion, IEAC regimen was well tolerated and replacement with idarubicin could be an alternative when carmustine was not available. |
format | Online Article Text |
id | pubmed-7895978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-78959782021-02-24 Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients Tian, Chen Li, Yueyang Liu, Su Chen, Zehui Zhang, Yizhuo Yu, Yong Yang, Hongliang Zhao, Haifeng Zhao, Zhigang Yuan, Tian Wang, Yafei Sci Rep Article High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) is still a consolidation treatment choice for relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients and some aggressive B-cell NHL as frontline therapy. Due to the shortage of carmustine, we switched to idarubicin-substituted BEAC (IEAC) conditioning regimen. We retrospectively compared the outcomes of 72 aggressive B-cell NHL patients treated with IEAC or BEAC regimens followed by ASCT as upfront consolidative treatment. The median time to neutrophil and platelet reconstitution showed no difference between IEAC and BEAC groups. IEAC regimen was well tolerated without increase of adverse events. Transplant-related mortality didn’t occur. The overall survival (OS) and progression-free survival (PFS) of IEAC group (33 and 23 months) were a little longer than that of BEAC group (30 and 18 months). However, due to the small sample numbers, there’s no significant difference in OS and PFS between IEAC and BEAC group with DLBCL or MCL. Multivariate analysis showed that AnnArbor staging, IPI score, lactate dehydrogenase level, remission of disease, modified regimen were related with PFS and OS. In conclusion, IEAC regimen was well tolerated and replacement with idarubicin could be an alternative when carmustine was not available. Nature Publishing Group UK 2021-02-19 /pmc/articles/PMC7895978/ /pubmed/33608570 http://dx.doi.org/10.1038/s41598-021-81944-8 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Tian, Chen Li, Yueyang Liu, Su Chen, Zehui Zhang, Yizhuo Yu, Yong Yang, Hongliang Zhao, Haifeng Zhao, Zhigang Yuan, Tian Wang, Yafei Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients |
title | Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients |
title_full | Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients |
title_fullStr | Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients |
title_full_unstemmed | Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients |
title_short | Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients |
title_sort | modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive b-cell non-hodgkin’s lymphoma patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895978/ https://www.ncbi.nlm.nih.gov/pubmed/33608570 http://dx.doi.org/10.1038/s41598-021-81944-8 |
work_keys_str_mv | AT tianchen modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT liyueyang modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT liusu modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT chenzehui modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT zhangyizhuo modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT yuyong modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT yanghongliang modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT zhaohaifeng modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT zhaozhigang modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT yuantian modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT wangyafei modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients |